GPS for Cell Therapy
TM
Media & Press Updates
Visicell Medical Receives $10,000 Award at BioTools Innovator 2025 Capstone Event
November 19, 2025
Visicell presented at the 2025 BioTools Innovator Capstone Event in San Diego as one of five Grand Prize finalists selected from a global pool of more than 400 applicants. As a finalist, VisiCELL received a $10,000 award in recognition of its innovative MRI-based cell tracking platform and its potential to advance visibility in cell therapy development and clinical translation. Participation in the BioTools Innovator accelerator and Capstone Event underscores continued validation of Visicell technology, team, and momentum heading into 2026.
Visicell named Grand Prize Finalist in BioTools Innovator 2025
October 28, 2025
Visicell has been selected as one of the Finalists in the BioTools Innovator 2025 program, recognizing the top life science tools and diagnostics startups from a global pool of more than 400 applicants. The Capstone Event, to be held November 18 in San Diego, will feature five finalists competing for the BioTools Innovator Grand Prize of $250,000 in non-dilutive funding.
Showcasing noninvasive imaging tools for CGT manufacturing at Hope Is Not a Workflow Symposium
August 12, 2025
Visicell participated in the Rapid-Fire Sessions at Hope Is Not a Workflow: Addressing the Hard Truths of CGT Manufacturing, held August 12, 2025, in San Diego. The symposium convened industry leaders, manufacturers, and innovators to discuss scalable, data-driven approaches for cell and gene therapy production. VisiCELL highlighted its VMI-Trac™ MRI-based cell-tracking technology and its potential to streamline translational workflows through quantitative, noninvasive imaging analytics.
Visicell named to BioTools Innovator 2025 cohort for life science tools innovation
June 10, 2025
Visicell Medical has been selected as a member of the BioTools Innovator 2025 Accelerator cohort — one of 31 life-science tools and diagnostics startups chosen from a competitive pool of over 400 applicants. The four-month program offers tailored mentorship, industry connections, and a chance to compete for $300,000 in cash awards, positioning Visicell for its next phase of growth.
Visicell honored at ISCT 2025 with Top Scoring Emerging Immunotherapy Abstract Award
May 29, 2025
Visicell received the Top Scoring Emerging Immunotherapy Abstract Award at the International Society for Cell & Gene Therapy (ISCT) 2025 Annual Meeting, held May 29 – June 1 in New Orleans, LA, for advancing MRI-based tracking of glioblastoma-targeted CAR T cells in solid-tumor immunotherapy.
Selected to present at MoFo’s Life Sciences/Therapeutics Pitch Day 2024
September 30, 2024
Visicell Medical was selected to present as a finalist in the Life Sciences/Therapeutics track at Morrison & Foerster’s Pitch Day, held September 26, 2024, at the firm’s Palo Alto office. The event gathered leading investors and emerging innovators developing next-generation therapeutics, offering each finalist a focused five-minute pitch and Q&A session with venture capital partners.
Visicell featured at Connect Venture Summit & Innovation Day 2024
September 24, 2024
VisiCELL Medical took part in Connect’s two-part event in San Diego on September 24, 2024: an invite-only Venture Summit bringing together 100+ venture investors, followed by the large-scale Innovation Day takeover at Petco Park with over 3,500 attendees and 200+ exhibiting companies.
Still Cool: Visicell named to Connect’s Cool Companies for a second year
April 8, 2024
Visicell Medical has once again been recognized as one of San Diego’s Connect Cool Companies, earning a place in the Class of 2024 after first being selected in 2023. Chosen from more than 190 applicants, this back-to-back recognition highlights VisiCELL’s continued innovation, growth momentum, and Series A readiness within the region’s thriving life-science and technology ecosystem.
Presented and exhibited at Advanced Therapies Congress 2024 – London
March 23, 2024
Visicell showcased its VMI-Trac™ MRI-based cell-tracking platform in the Start-Up Zone and presented in the Start-Up Track at Advanced Therapies Congress 2024, engaging global leaders across the cell and gene therapy ecosystem.
Featured as a Connect Cool Company at Venture Summit & Innovation Day 2023
September 14, 2023
As part of the Connect Cool Companies Class of 2023, Visicell was invited to participate in Connect’s Venture Summit and exhibit at Innovation Day 2023, held September 14 at Petco Park in San Diego. The event convened over 3,500 members of the regional innovation community and more than 200 exhibiting startups, featuring investor panels, emerging company showcases, and live networking.
Recognized as a Connect Cool Company
April 13, 2023
Visicell Medical was selected for the Connect Cool Companies Class of 2023, recognizing startups demonstrating strong innovation and Series A investment readiness across Southern California’s life-science and technology sectors. The program connects high-potential founders with investors and strategic partners, spotlighting companies poised for growth and impact in the innovation ecosystem.
Advancing stem cell Imaging: Poster presentation at Cell Symposium – Cedars-Sinai
December 8, 2022
Visicell Medical presented a scientific poster at the Cell Symposium: Advances in Therapeutic Applications of Stem Cells, held December 8–10, 2022 at Cedars-Sinai Medical Center in Los Angeles. The presentation highlighted the company’s VMI-Trac Duo, a dual-labeling agent that enables complementary imaging by MRI and fluorescence, offering researchers a versatile, multi-modal approach to track and characterize therapeutic cells in vivo. Hosted by Cell Press in collaboration with Cedars-Sinai, the symposium convened leading experts in regenerative medicine, biomanufacturing, and clinical translation of stem-cell therapies.
Selected to participate in Advanced Therapies 2022 – London
May 23, 2022
Visicell Medical was among the start-ups developing particularly innovative ideas selected to participate in Advanced Therapies 2022, Europe’s leading cell and gene therapy congress, showcasing breakthrough technologies shaping the future of advanced therapeutics.
Visicell presents at Cell & Gene Meeting on the Mesa 2021
October 15, 2021
Visicell Medical presented its VMI-Trac™ MRI-based in vivo cell-tracking platform at the 2021 Cell & Gene Meeting on the Mesa, held October 12–14 in Carlsbad, California. The presentation showcased how Visicell’s imaging analytics enable real-time biodistribution and pharmacokinetic insight to accelerate the development of safer, more effective cell therapies.
Visicell joins StartX Spring 2021 cohort
January 12, 2021
Visicell Medical will participate in the 2021 StartX accelerator program, a Stanford-affiliated community of founders and innovators driving breakthroughs in medicine and life science technology. Through StartX, the Visicell team will engage with mentors, investors, and clinical experts to support the advancement of its VMI-Trac™ MRI-based in vivo cell-tracking platform.
Visicell secures angel Investment and runner-up recognition at 2020 San Diego Angel Conference
March 29, 2020
VisiCELL Medical received runner-up recognition and a $100,000 investment at the 2020 San Diego Angel Conference (SDAC), reflecting strong investor confidence in the company’s VMI-Trac™ MRI-based in vivo cell-tracking platform. Selected as one of six finalists from a competitive pool of 105 applicants, this milestone underscores VisiCELL’s growing momentum in advancing data-driven, noninvasive imaging technologies that enable safer and more effective development of next-generation cell therapies.
Quarter-finalists announced for the 2nd annual San Diego Angel Conference
February 3, 2020
Visicell is one of twenty-seven companies advancing to the quarterfinal round of San Diego Angel Conference from a pool of more than 100 startup companies. The winning company will take home a guaranteed $200,000 investment from angels at the main event on March 28.
-
We always have a story to tell, so check our news section often and contact us if you need more information!